TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38862251
Drug: Neoadjuvant toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant toripalimab 240 mg every 3 weeks (three cycles) combined with axitinib 5 mg twice daily for up to 12 weeks.
Study: 38862308
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care plus peer-led vaccine counseling
Study: 38862815
Drug: Self-administered mindfulness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered mindfulness interventions
Study: 38862908
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg/day orally for 14 days on and 7 days off) and nivolumab (360 mg every 3 weeks)
Study: 38863026
Drug: Hydrogen-oxygen gas
Normalized name: oxygen Gas for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-oxygen gas mixture inhalation (8 hours per day, 3 L/min, hydrogen concentration of 67%, oxygen concentration of 33%)
Study: 38863026
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation (8 hours per day, 3 L/min, oxygen concentration of 33%)
Study: 38863155
Drug: Fidanacogene elaparvovec
Normalized name: Fidanacogene elaparvovec
DrugBank: Fidanacogene elaparvovec (DB16783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidanacogene elaparvovec (gene therapy)
Study: 38863591
Drug: Immunomodulatory formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory formula with extra virgin olive oil (administered 5 days before surgery)
Study: 38863672
Drug: Intensive inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive inpatient trauma treatment program with prolonged exposure (PE), eye movement desensitization and reprocessing (EMDR), and therapist rotation (TR)
Study: 38863672
Drug: Intensive inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive inpatient trauma treatment program
Study: 39233711
Drug: Fostemsavir +
Normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostemsavir + optimized background therapy
Study: 38864524
Drug: HIL-214 (formerly
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIL-214 (formerly TAK-214) vaccine
Study: 38864600
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 300 mg b.i.d. plus 1.2 mg midazolam (MDZ) on Days 11 and 14
Study: 38864600
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 300 mg b.i.d. alone on Days 8-10
Study: 38864600
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 200 mg b.i.d. alone on Days 5-7
Study: 38864600
Drug: Midazolam (MDZ)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (MDZ) 1.2 mg alone on Day 1
Study: 38864600
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 300 mg b.i.d. on Days 11 and 14
Study: 38864969
Drug: Intralipid 20%
Normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 20% (1.5 ml/kg) administered 3 min before aortic cross unclamping
Study: 38864969
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's Lactate (control group) administered 3 min before aortic cross unclamping
Study: 38865064
Drug: Zinc-vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc-vitamin E group (n = 40) received oral zinc (120 mg) and vitamin E (1200 IU) before surgery, followed by 30 mg of zinc and 200 IU of vitamin E daily until 21 days after surgery.
Study: 38865084
Drug: Maternal immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal immune responses to CMV, including anti-pentamer immunoglobulin G antibody concentration and viral load in saliva.
Study: 38865129
Drug: Limosilactobacillus reuteri
Normalized name: Limosilactobacillus reuteri
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limosilactobacillus reuteri high dose (5×10^9 CFU)
Study: 38865129
Drug: Limosilactobacillus reuteri
Normalized name: Limosilactobacillus reuteri
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limosilactobacillus reuteri low dose (5×10^8 CFU)
Study: 38865168
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acids (2 g per kilogram of ideal body weight per day)
Study: 38865168
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acids
Study: 38865296
Drug: Clinical practices
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical practices and interventions (e.g., warm compresses, manual perineal protection, vaginal examinations, perineal massage, levator pressure, intermittent catheterization, fundal pressure, episiotomy)
Study: 38865704
Drug: Web-based therapist-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based therapist-guided mindfulness-based cognitive behavioral therapy (CBT-M)
Study: 38865704
Drug: Web-based therapist-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based therapist-guided cognitive behavioral therapy (CBT)
Study: 38866072
Drug: Minnelide 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minnelide 1.5 mg as monotherapy (Regimen A)
Study: 38866072
Drug: Minnelide 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minnelide 1.25 mg once daily for 21 days Q4 weeks as monotherapy (MTD)
Study: 38866072
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Minnelide plus paclitaxel (Regimen B & C)
Study: 38866095
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available treatment without ANH
Study: 38866559
Drug: PENG block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: PENG block (20 mL of 0.3% ropivacaine)
Study: 38866559
Drug: SIFICB (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIFICB (30 mL of 0.3% ropivacaine)
Study: 38866567
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) in addition to usual care (UC)
Study: 38866575
Drug: Internet-based individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based individual therapy for insomnia (iCBT-I) + TAU
Study: 38866575
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy for insomnia (GCBT-I) + TAU
Study: 38866822
Drug: CAR T
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR T cell therapy (as referenced in the BNT-211-01 trial, NCT04503278)
Study: 38867006
Drug: Yttrium-90-anti-CD66 antibody
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yttrium-90-anti-CD66 antibody
Study: 38867018
Drug: HFNC flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC flow 30 l/min, open mouth
Study: 38867018
Drug: HFNC flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC flow 30 l/min, closed mouth
Study: 38867018
Drug: HFNC flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC flow 70 l/min, open mouth
Study: 38867018
Drug: HFNC flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC flow 70 l/min, closed mouth
Study: 38867018
Drug: 95% Limits
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95% Limits of Agreement for 30 l/min - closed mouth
Study: 38867018
Drug: 95% Limits
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95% Limits of Agreement for 30 l/min - open mouth
Study: 38867018
Drug: 95% Limits
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95% Limits of Agreement for 70 l/min - closed mouth
Study: 38867018
Drug: 95% Limits
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95% Limits of Agreement for 70 l/min - open mouth
Study: 38867164
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy protocols
Study: 38867164
Drug: Broad-spectrum antibiotic
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotic therapy ≥ 4 days
Study: 38867164
Drug: Prescribing ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribing ≥ 2 antibiotics
Study: 38867195
Drug: Bowen's Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowen's Therapy
Study: 38867220
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) - primarily herbal medicine (HM)
Study: 38867257
Drug: Tunlametinib 9
Normalized name: Tramétinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tunlametinib 9 mg plus vemurafenib 720 mg, twice daily (BID)
Study: 38867309
Drug: Intensive Prolonged
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Prolonged Exposure (iPE) therapy
Study: 38867309
Drug: Standard weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weekly delivered sessions of Prolonged Exposure (PE) therapy
Study: 38867317
Drug: Personalized music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized music therapy (MT) for at least 2 hours per day
Study: 38867317
Drug: Generalized music
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalized music therapy (MT) for 12.5 hours per day, subdivided into fifteen 50-min periods
Study: 38867317
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without music therapy (MT)
Study: 38867317
Drug: Generalized music
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalized music therapy (MT)
Study: 38867349
Drug: Trametinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (oral MEK1/2 inhibitor), administered for a maximum of 12 cycles.
Study: 38867582
Drug: Azacitidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (5 days treatment prior to chemotherapy)
Study: 38869701
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at 0.025 µg/kg/min
Study: 38869701
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at 0.05 µg/kg/min
Study: 38869701
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at 0.075 µg/kg/min
Study: 38869746
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg orally BID plus celecoxib 200 mg orally once daily for 12 weeks
Study: 38869746
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets BID plus celecoxib 200 mg orally once daily for 12 weeks
Study: 38869771
Drug: Talazoparib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib monotherapy
Study: 38869865
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of TKI treatment and follow-up every 3 months.
Study: 38869865
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to next treatment.
Study: 38869931
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfusions initiated at hemoglobin level ≤10 g/dL)
Study: 38869931
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (transfusions initiated at hemoglobin level ≤7 g/dL)
Study: 38869978
Drug: Antidepressants (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (specific mention of paroxetine and sertraline)
Study: 38869987
Drug: Avenciguat 1
Normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avenciguat 1 mg twice-daily
Study: 38869987
Drug: Avenciguat 2
Normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avenciguat 2 mg twice-daily
Study: 38869987
Drug: Avenciguat 3
Normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avenciguat 3 mg twice-daily
Study: 38870076
Drug: Conventional diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diabetes treatments
Study: 38870103
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Norepinephrine)
Study: 38870156
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment as usual
Study: 38870749
Drug: Qilong capsule
Normalized name: TOCOPHEROL 1 g in 99 g TOPICAL CREAM [Guangzhou Yilong Cosmetics Co., Ltd]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilong capsule (QLC) combined with conventional treatment (CT)
Study: 38870749
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CT) alone
Study: 38870931
Drug: Serplulimab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab (300 mg) plus HLX04 (7.5 mg/kg) and XELOX
Study: 38870931
Drug: Placebo (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (300 mg) plus bevacizumab (7.5 mg/kg) and XELOX
Study: 38870977
Drug: Nanoliposomal irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoliposomal irinotecan (70 mg/m²) plus fluorouracil plus leucovorin
Study: 38871657
Drug: Tacrolimus 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0.02 mg/kg intravenous infusion over 4 hours prior to organ retrieval
Study: 38872109
Drug: Dose-matched PT
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched PT sessions
Study: 38872193
Drug: Diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet + Supplementation: individualized diet supplemented with 604 mg of omega-3 fatty acids, three times a day
Study: 38872193
Drug: Diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet + Placebo: individualized diet + 1 g of soybean oil
Study: 38872193
Drug: Placebo: 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 1 g of soybean oil daily, no dietetic intervention
Study: 38872204
Drug: Low-intensity intervention
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity intervention group (bi-monthly online lifestyle-related health advice)
Study: 38872829
Drug: VTS (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTS (not receiving Botulinum treatment)
Study: 38872994
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg/day
Study: 38873632
Drug: Upadacitinib 6
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib 6 mg (UPA6)
Study: 38873632
Drug: Upadacitinib 11
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib 11 mg (UPA11)
Study: 38873632
Drug: Upadacitinib 22
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib 22 mg (UPA22)
Study: 38873634
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TRAN) - 1-g slow intravenous infusion within 5 minutes from childbirth
Study: 38873723
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg) plus standard care
Study: 38873885
Drug: Adjunctive azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive azithromycin (500 mg)
Study: 38873934
Drug: vemurafenib at
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib at 550 mg/m2 (maximum 960 mg/dose) orally twice daily for 28-day cycles
Study: 38874333
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ipilimumab and Nivolumab (IPI + NIVO)
Study: 38874333
Drug: Control (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Standard treatment)
Study: 38875119
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa (BA) plus GemCis (gemcitabine 1000 mg/m2 + cisplatin 25 mg/m2 on days 1 and 8 every 3 weeks for 8 cycles)
Study: 38875119
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus GemCis (gemcitabine 1000 mg/m2 + cisplatin 25 mg/m2 on days 1 and 8 every 3 weeks for 8 cycles)
Study: 38875121
Drug: Long-acting dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting dexamethasone viscous gel delivered by transforaminal injection
Study: 38875111
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole (40 mg daily)
Study: 38875279
Drug: LUNA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUNA treatment delivered twice weekly for 10 weeks via videoconferencing (Zoom)
Study: 38875279
Drug: LUNA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUNA treatment
Study: 38875579
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) models using weekly and daily DPP data sets (328,821 and 704,242 records)
Study: 38875880
Drug: Office-based addiction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based addiction treatment (OBAT)
Study: 38876647
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy interventions (MTIs) including passive joint mobilisation and soft tissue manipulation, administered for eight weekly 30-min sessions.
Study: 38876647
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy interventions (MTIs)
Study: 38877077
Drug: Happy Mother-Healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Happy Mother-Healthy Baby program (Cognitive Behavior Therapy)
Study: 38877450
Drug: Laparoscopic resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic resection rectopexy (L-RRP) with mesh-sacrocolpopexy (L-SCP) using synthetic mesh (SM)
Study: 38877450
Drug: Laparoscopic resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic resection rectopexy (L-RRP) with mesh-sacrocolpopexy (L-SCP) using biological mesh (BM)
Study: 38877571
Drug: Haemoglobin values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin values < 7.5 g/dL
Study: 38877571
Drug: Haemoglobin values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin values between 7.5-9.5 g/dL
Study: 38877571
Drug: Anaemia (Hb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaemia (Hb < 9.5 g/dL)
Study: 38877608
Drug: Adapted Test-and-Exercise
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted Test-and-Exercise home-based exercise program (8 weeks, once per week with a physiotherapist, twice per week with caregiver or independently)
Study: 38878209
Drug: Modafinil 400
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400 mg QD from Day 15 to Day 21
Study: 38878209
Drug: Encorafenib 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib 450 mg QD from Day 1
Study: 38878209
Drug: Binimetinib 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib 45 mg BID from Day 1
Study: 38878337
Drug: Internet-based ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based ACT combined with Treatment as Usual (iACT + TAU)
Study: 38879045
Drug: Through-the-needle injection-capable
Normalized name: BRIEF,TRANQUILITY ALL THROUGH THE NIGHT BRIEF MEDIUM #2185
Approvals — FDA: no, EMA: no, PMDA: no
Description: Through-the-needle injection-capable electrosurgical knife
Study: 38879393
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily (cohort 1)
Study: 38879393
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily (cohort 2)
Study: 38879455
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) pulse oximetry combining oxygenation, perfusion data, and pulse delay at 2 time points
Study: 38879455
Drug: ML algorithms
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML algorithms at 1 versus 2 time points with/without pulse delay
Study: 38879518
Drug: Delayed Cold-Stored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Cold-Stored Platelets (DCSP) - ABO-identical, buffy-coat, pathogen-reduced platelets in platelet additive solution maintained at 22 °C for up to 4 days then placed at 4 °C for a minimum of 24 h, with expiration at 14 days after collection. Duration: from termination of cardiopulmonary bypass to 24 h after, with a maximum of two doses.
Study: 38879571
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Pycnogenol® daily for 12 weeks
Study: 38879802
Drug: Linvoseltamab 200
Normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linvoseltamab 200 mg